Climber Capital
PFE icon

Climber Capital’s Pfizer PFE Stock Holding History

Climber Capital’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$412K Buy
+15,220
New +$405K 0.25% 54
2026
Q2 		– Sell
-19,350
Closed -$543K – 68
2026
Q1 		$543K Buy
+19,350
New +$515K 0.36% 54

Other funds holding PFE

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Pzena Investment Management
Pzena Investment Management New York $34.1B AUM 26.62% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Climber Capital's PFE Position: Q3 2026 in Review

Climber Capital opened a new position in Pfizer (PFE) in Q3 2026: 15,220 shares worth $412K. The stake represents 0.25% of the portfolio and ranks #54 among its holdings. This is a return to the name: Climber Capital previously reported a position in PFE as recently as Q1 2026.

Climber Capital first reported a position in PFE in Q1 2026 and has held it in 2 quarters since. The position peaked at $543K in Q1 2026. 1,285 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Climber Capital held 15,220 shares of Pfizer worth $412K as of Q3 2026.
  • Pfizer was a new Climber Capital position in Q3 2026.
  • Pfizer made up 0.25% of Climber Capital's portfolio in Q3 2026, its #54 holding.
  • Climber Capital first reported a position in Pfizer in Q1 2026 and has held it in 2 quarters since.
  • Climber Capital's Pfizer position peaked at $543K in Q1 2026.
  • 1,285 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Climber Capital's 13F filing for Q3 2026, filed 20 Oct 2026.